Archives

What happens after Ozempic shocked researchers

Stopping popular weight-loss injections like Ozempic or Mounjaro might not trigger the dramatic rebound many fear. A large real-world study of nearly 8,000 patients found that most people who discontinue these drugs manage to keep the weight off—or even continue losing—by restarting treatment, switching medications, or adopting lifestyle changes. While earlier clinical trials suggested rapid weight regain, this new evidence paints a more hopeful picture.

High-Dose Wegovy Wins FDA Approval

(MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose — three times the strength…

Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

Study: GLP-1RAs associated with less risk of mental illness getting worse

In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).

Triple crown: T2D purse for Lilly’s phase III retatrutide?

Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in type 2 diabetes (T2D).